News
In just eight years, the NIH National Institute of Allergy and Infectious Diseases moved from identifying an ultra-rare genetic disorder, CD55 deficiency, hyperactivation of the complement, angiopathic thrombosis, and protein-losing enteropathy (CHAPLE) to FDA approval of its first treatment option
The Federal Laboratory Consortium for Technology Transfer (FLC) is honoring 32 FLC Award winners (three of whom are from NIH) from 8 federal agencies for their contributions to technology transfer, which turns cutting-edge research into impactful products and services. The FLC represents over 300
Register to attend the National Cancer Institute Technology Transfer Center's first NIH technology webinar of the year on May 22nd, 2024 at 11AM ET. Attendees will learn about a potential, novel treatment for Retinitis Pigmentosa (RP). Over 100,000 people in the U.S. and 1.5 million people worldwide
A mouse cell line engineered to produce camelid nanobodies for use against infectious diseases or for basic applications is available for licensing. Nanobodies: have equivalent binding specificity to antigens as antibodies but are more heat- and detergent-stable. can target epitopes that are not